Cardiff Oncology (CRDF) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Neuraxis (NRXS) has outperformed Cardiff Oncology (CRDF) over the past year, gaining 132.6% versus a loss of 51.1%. Neuraxis is the larger company by market cap ($87.0 million vs $84.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDF | NRXS |
|---|---|---|
| Share price | $1.08 | $6.93 |
| Market cap | $84.02M | $87.03M |
| 1-day change | +1.89% | +2.36% |
| YTD return | -61.57% | +52.64% |
| 1-year return | -51.13% | +132.55% |
| 5-year return | -83.13% | — |
| EPS (TTM) | $-0.60 | $-0.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.31 | $9.33 |
| 52-week low | $0.76 | $2.21 |
| Distance from 52-week high | -67.37% | -25.72% |
| Analyst consensus | none | none |
| Avg. price target upside | +437.96% | +58.73% |
| Average volume | 1.04M | 107.56K |
| Shares outstanding | 77.80M | 12.56M |
| Employees | 30 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed CRDF by 183.7 percentage points over the past year.
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
CRDF vs NRXS FAQ
Which is bigger, Cardiff Oncology or Neuraxis?
Neuraxis (NRXS) is larger, with a market capitalization of $87.03M compared with $84.02M for Cardiff Oncology (CRDF).
Which stock has performed better over the past year, CRDF or NRXS?
NRXS returned +132.55% over the past 12 months, compared with -51.13% for CRDF (price return, excluding dividends). Past performance does not predict future results.
Are Cardiff Oncology and Neuraxis in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cardiff Oncology and Biotechnology: Electromedical & Electrotherapeutic Apparatus for Neuraxis.